Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+
- PMID: 19670224
- PMCID: PMC2782577
- DOI: 10.1002/pros.21020
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+
Abstract
Background: Prostate-infiltrating CD8(+) T lymphocytes (CD8(+) PIL) are prevalent in men with prostate cancer (PCa), however, it is unclear whether the presence of such cells reflects a non-specific immune infiltrate or an oligoclonal, antigen-driven adaptive immune response.
Methods: We investigated the complexity of the T-cell receptor (TCR) repertoire in the prostate gland by examining the diversity of CD8(+) TCR beta chain variable region (Vbeta) gene sequences in both the peripheral blood and prostates of cancer patients. Vbeta repertoire analysis was performed by family-specific Vbeta spectratyping and flow cytometry, as well as direct sequence analysis (5' RACE and cloning). Programmed cell death 1 (PD-1 or PDCD1) expression on peripheral blood CD8(+) T cells and CD8(+) PIL was analyzed by flow cytometry.
Results: CD8(+) PIL isolated from cancer patients exhibited restricted TCR Vbeta gene usage, and identical clones were identified in multiple sites within the prostate. Furthermore, CD8(+) PIL express high levels of the inhibitory receptor PD-1, a cell surface protein associated with an "exhausted" CD8(+) T-cell phenotype.
Conclusions: CD8(+) PIL appear to have undergone clonal expansion in response to an as yet unidentified antigen; however, due to the high expression of PD-1, these cells are likely incapable of mounting an effective immune response. The results provide an important basis for further efforts aimed at the identification of specific antigens involved in prostatic inflammation, and suggest that PD-1 blockade may be useful in immunotherapy for PCa.
Figures




Similar articles
-
T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.Cancer Immunol Immunother. 2018 Nov;67(11):1767-1776. doi: 10.1007/s00262-018-2228-7. Epub 2018 Aug 22. Cancer Immunol Immunother. 2018. PMID: 30167863 Free PMC article.
-
Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck.Clin Cancer Res. 2006 Apr 15;12(8):2394-403. doi: 10.1158/1078-0432.CCR-05-1818. Clin Cancer Res. 2006. PMID: 16638844
-
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17.Cell Rep Med. 2020 Oct 20;1(7):100127. doi: 10.1016/j.xcrm.2020.100127. eCollection 2020 Oct 20. Cell Rep Med. 2020. PMID: 33205076 Free PMC article.
-
Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma.Front Immunol. 2019 Jun 18;10:1336. doi: 10.3389/fimmu.2019.01336. eCollection 2019. Front Immunol. 2019. PMID: 31275310 Free PMC article.
-
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.Front Immunol. 2018 Jan 22;9:14. doi: 10.3389/fimmu.2018.00014. eCollection 2018. Front Immunol. 2018. PMID: 29403496 Free PMC article. Review.
Cited by
-
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.Int J Mol Sci. 2016 Jul 18;17(7):1151. doi: 10.3390/ijms17071151. Int J Mol Sci. 2016. PMID: 27438833 Free PMC article. Review.
-
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors.Onco Targets Ther. 2016 Oct 6;9:6075-6082. doi: 10.2147/OTT.S115054. eCollection 2016. Onco Targets Ther. 2016. PMID: 27785054 Free PMC article.
-
Immunotherapy earns its spot in the ranks of cancer therapy.J Exp Med. 2012 Feb 13;209(2):201-9. doi: 10.1084/jem.20112275. J Exp Med. 2012. PMID: 22330682 Free PMC article.
-
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?Front Immunol. 2021 Dec 23;12:773168. doi: 10.3389/fimmu.2021.773168. eCollection 2021. Front Immunol. 2021. PMID: 35003090 Free PMC article. Review.
-
PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma.Oncol Lett. 2017 Jul;14(1):250-256. doi: 10.3892/ol.2017.6105. Epub 2017 Apr 28. Oncol Lett. 2017. PMID: 28693161 Free PMC article.
References
-
- Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 2005;25(6C):4435–4438. - PubMed
-
- Striebich CC, Falta MT, Wang Y, Bill J, Kotzin BL. Selective accumulation of related CD4+ T cell clones in the synovial fluid of patients with rheumatoid arthritis. J Immunol. 1998;161(8):4428–4436. - PubMed
-
- Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate. 2008;68(3):306–320. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials